» Articles » PMID: 30360393

Association of Adiponectin and Rs1501299 of the Gene with Prediabetes in Jordan

Overview
Journal Biomolecules
Publisher MDPI
Date 2018 Oct 27
PMID 30360393
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes mellitus (T2DM) is a worldwide health problem caused by resistance to insulin action. This chronic debilitating diseaseis preceded by a stage, known as prediabetes, in which a healthy lifestyle can delay the disease. The discovery of biochemical changes in prediabetes is important to identify individuals at risk of developing T2DM and in explaining disease pathogenesis. Adiponectin is secreted by fat cells and is linked with insulin resistance. Adiponectin levels are dysregulated in prediabetic subjects. This relationship had not been tested in Jordan. We recruited 130 subjects with prediabetes and 130 control subjects. We measured serum levels of adiponectin and genotyped subjects for three single nucleotide polymorphisms (SNPs) in the gene; rs266729, rs1501299 and rs2241766. In multivariate analysis, we found that serum adiponectin lowers the risk of prediabetes ( = 0.002; odds ratio (OR), 0.764; 95% confidence interval (CI), 0.646⁻0.905). The rs1501299 SNP of the gene was associated with prediabetes in our population ( = 0.041). Specifically, in multivariate analysis, the GT genotype of rs1501299 increased the risk of prediabetes ( = 0.010; OR, 2.350; 95% CI, 1.231⁻4.486) as well as the TT genotype ( = 0.006; OR, 4.774; 95% CI, 1.551⁻14.693). Our findings indicate that serum adiponectin and SNPs in the gene are associated with prediabetes in Jordan.

Citing Articles

Serum adiponectin and peroxisome proliferator-activated receptors-γ levels in obese patients with and without prediabetes.

Gul M, Tozcu D, Tekcan A, Capraz M, Dortok Demir H Rev Assoc Med Bras (1992). 2024; 70(3):e20231000.

PMID: 38655997 PMC: 11045203. DOI: 10.1590/1806-9282.20231000.


Therapeutic potential of adiponectin in prediabetes: strategies, challenges, and future directions.

Abdalla M Ther Adv Endocrinol Metab. 2024; 15:20420188231222371.

PMID: 38250316 PMC: 10798122. DOI: 10.1177/20420188231222371.


Serum Leptin Receptor and the rs1137101 Variant of the Gene Are Associated with Bladder Cancer.

Alfaqih M, Elsalem L, Nusier M, Mhedat K, Khader Y, Ababneh E Biomolecules. 2023; 13(10).

PMID: 37892180 PMC: 10604959. DOI: 10.3390/biom13101498.


Leptin and the rs2167270 Polymorphism Are Associated with Glycemic Control in Type Two Diabetes Mellitus Patients on Metformin Therapy.

Alfaqih M, Aljanabi M, Ababneh E, Khanfar M, Alqudah M, Sater M Medicina (Kaunas). 2023; 59(5).

PMID: 37241229 PMC: 10221967. DOI: 10.3390/medicina59050997.


Genetic variation in the ADIPOQ gene and serum adiponectin increase the risk of bladder cancer.

Elsalem L, Alfaqih M, Al Bashir S, Halalsheh O, Basheer H, Mhedat K J Appl Biomed. 2022; 20(3):106-113.

PMID: 36218131 DOI: 10.32725/jab.2022.012.


References
1.
Park K, Park K, Kim M, Kim H, Suh Y, Ahn J . Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004; 63(2):135-42. DOI: 10.1016/j.diabres.2003.09.010. View

2.
Kern P, Di Gregorio G, Lu T, Rassouli N, Ranganathan G . Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52(7):1779-85. DOI: 10.2337/diabetes.52.7.1779. View

3.
Khabour O, Mesmar F, Alatoum M, Gharaibeh M, Alzoubi K . Associations of polymorphisms in adiponectin and leptin genes with men's longevity. Aging Male. 2010; 13(3):188-93. DOI: 10.3109/13685531003657800. View

4.
Alfaqih M, Abu-Khdair Z, Saadeh R, Saadeh N, Al-Dwairi A, Al-Shboul O . Serum Branched Chain Amino Acids Are Associated with Type 2 Diabetes Mellitus in Jordan. Korean J Fam Med. 2018; 39(5):313-317. PMC: 6166113. DOI: 10.4082/kjfm.17.0122. View

5.
Lago R, Singh P, Nesto R . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370(9593):1129-36. DOI: 10.1016/S0140-6736(07)61514-1. View